With comprehensive profiling of Tau proteins—including both brain-specific and peripheral pTau217, pTau181, pTau231 and MAPT, —NULISA provides powerful insights into the disease heterogeneity of tauopathies. Beyond tau coverage, NULISAseq CNS Disease Panel 120 includes multiplex detection of important biomarkers across amyloid pathology, neurodegeneration, inflammation, synaptic and vascular processes.
By leveraging multiplexed assays for proteins implicated in neurodegenerative and inflammatory pathways, researchers and clinicians can now gain unprecedented insight into the molecular fingerprints that define distinct neurological disorders. This approach not only supports early diagnosis but also enables nuanced monitoring of disease progression, response to therapies, and patient stratification—paving the way for truly personalized interventions.
Alzheimer’s Disease and Dementia Research Given the heterogeneous pathology of AD and mixed dementia, inflammation, synaptic, and vascular markers can play a key role in understanding disease pathophysiology. By measuring multiple CNS proteins simultaneously, Alamar’s ultra-sensitive NULISA™ multiplex panels can monitor changes across key processes to provide insights beyond the established AT(N) biomarkers. Karikari, et al. demonstrates how multiplexed, blood-based profiling can provide a comprehensive view of AD-associated proteomic changes, consistent with the recently revised biological and diagnostic framework.
In addition to p-tau217 fourteen markers were shown to be significantly decreased in Aβ-PET + participant including TIMP3, BDNF, MDH1, and several cytokines. Longitudinally, FGF2, IL4, and IL9 exhibited Aβ PET-dependent yearly increases in Aβ-PET + participants.
Novel plasma biomarkers associated with longitudinal changes in tau PET identified proteins associated with neuroinflammation, synaptic function, and cerebrovascular integrity including; CHIT1, CHI3L1, NPTX1, PGF, PDGFRB, and VEGFA.
Frontotemporal Dementia (FTD)The identification of reliable blood-based biomarkers that can distinguish frontotemporal dementia (FTD) from other neurodegenerative conditions is crucial. Recent research has demonstrated the efficacy of ultra-sensitive NULISA™ multiplex panels in detecting proteomic signatures in serum and plasma. These include key early disease biomarkers such as TDP-43, pTDP-43, NfL, Tau, and others associated with FTD pathology.
What the data shows:
Ashton, et al. identified of over 60 differentially expressed plasma proteins. NfL exhibited the most significant fold change, alongside Neurogranin, superoxide dismutase, and TDP-43, underscoring their potential as translatable biomarkers in sporadic FTD.
Malpetti, et al. observed lower levels of CRH and NfL in FTD patients; elevated levels of PSEN1, PARK7, and PGK1—associated with amyloid processing and metabolic dysregulation as well as a strong correlation between plasma NfL and survival in FTD and PSP, validating its utility for disease monitoring and trial endpoints. Several inflammation biomarkers from the NULISA inflammation panel were also elevated in FTD patients, with AREG and CD276 showing the most significant increases. Additional upregulated biomarkers included TREM2, Lamp3, CCL7, IL-17A and IL-17F.
Lewy Body Dementia / Dementia with Lewy Bodies (LBD/DLB)The development of blood-based biomarkers to distinguish DLB from Alzheimer’s disease (AD) and other neurodegenerative disorders remain an urgent need. Recent publications have shown the utility of the ultra-sensitive NULISA multiplex panels simultaneously profile both known and novel biomarkers to discover blood-based proteomic signatures associated with DLB that distinguish between AD and DLB.
What the data shows:
Ashton, et al. carried out NULISAseq analysis in plasma samples of LB SAA+ versus AD SAA– patients showing 15 differentially changed proteins between symptomatic patients with and without αSyn pathology. After multiple testing correction, Aβ42 & VEGF vascular endothelial growth were seen to be upregulated with both p-tau217, & ENO2 being downregulated.
Malpetti, et al. used NULISA CNS Disease & Inflammation Panels to simultaneously profile NfL, GFAP, p-tau217, p-tau231, and p-tau181 in LBD and AD patients. Beyond the common dementia-relevant markers – CRH emerged as a biomarker of interest with lower levels strongly associated with worse survival in LBD patients.
Progressive Supranuclear Palsy (PSP)The development of blood-based biomarkers to distinguish PSP from other neurodegenerative disorders is an urgent need. In a recent publication, Malpetti, et al. showcased the utility of ultra-sensitive NULISA multiplex panels for simultaneous profiling across key CNS Disease & Inflammation biomarkers to identify disease-specific patterns in serum samples.
What the data shows:
Serum NfL levels are promising blood-based biomarkers for tracking disease progression and prognosis in PSP, outperforming other markers like p-tau217, p-tau231, and GFAP. PSP patients show increased proinflammatory proteins (OSM, MMP9, CCL7) and anti-inflammatory proteins (CD276, AREG), with IL1RN and HGF also elevated. Additional markers such as SQSTM1 and PSEN1 are higher in PSP and help distinguish it from AD/MCI+. New assays targeting brain-derived tau proteins (MAPT, pTau217, pTau181, pTau231) expand the capabilities of the NULISAseq CNS Disease 120 Panel for identifying blood-based biomarkers in PSP.
Tuesday, April 08, 2025 | 2pm EDT / 11am PDT Featuring: Laura Ibáñez, PhD Assistant Professor of Psychiatry, Washington University of Medicine Carlos Cruchaga, PhD
Featuring: Maura Malpetti, PhD UK DRI Emerging Leader Race Against Dementia ARUK Fellow Senior Research Associate University of Cambridge Sterling Johnson, PhD Professor of Geriatrics
Featuring: Sterling Johnson, PhD Professor of Geriatrics and Dementia, Department of Geriatrics and Gerontology, University of Wisconsin Alex Forrest-Hay VP of Sales Alamar Biosciences VIEW
Featuring: Nicholas Ashton, PhD Associate Professor of Neurochemistry University of Gothenburg Alex Forrest-Hay VP of Sales Alamar Biosciences VIEW ON DEMAND The advancement in ultra-sensitive
Featuring: Henrik Zetterberg, MD, PhD Professor of Neurochemistry, University of Gothenburg Doug Hinerfeld, PhD Senior Director of Application Support, Alamar Biosciences VIEW ON DEMAND Brain-derived
Tuesday, April 08, 2025 | 2pm EDT / 11am PDT Featuring: Laura Ibáñez, PhD Assistant Professor of Psychiatry, Washington University
Featuring: Maura Malpetti, PhD UK DRI Emerging Leader Race Against Dementia ARUK Fellow Senior Research Associate University of Cambridge Sterling
Featuring: Sterling Johnson, PhD Professor of Geriatrics and Dementia, Department of Geriatrics and Gerontology, University of Wisconsin Alex Forrest-Hay VP
Featuring: Nicholas Ashton, PhD Associate Professor of Neurochemistry University of Gothenburg Alex Forrest-Hay VP of Sales Alamar Biosciences VIEW ON
Featuring: Henrik Zetterberg, MD, PhD Professor of Neurochemistry, University of Gothenburg Doug Hinerfeld, PhD Senior Director of Application Support, Alamar
Multiplex analysis of biologically informed content with the highest-sensitivity and broadest dynamic range.
Profile Biomarkers of CNS Disease at the Lowest Limit of Detection
Simultaneous analysis of 120 proteins from a single 25ul sample with fg/ml sensitivity empowers researchers to detect disease earlier and differentiate between clinically similar phenotypes.
Detect More Differences between healthy and disease
Designed to provide the most comprehensive coverage of inflammatory pathways with unparalleled sensitivity, broad dynamic range, and exceptional detectability, this innovative panel is your ultimate solution for decoding complex cytokine pathways and comparing baseline levels in normal healthy individuals to inflammatory disease.
Discover More Biology in preclinical models
With the largest multiplexed protein panel for mouse studies, researchers can comprehensively measure inflammation from precious small volume samples and maximize the information captured in basic research and preclinical studies.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.